drugset / Trial / NCT01723982

Barusiban Subcutaneously for Reducing Implantation Failure Due to Uterine Contractions

NCT01723982

Phase 2 Completed 256 enrolled Ferring Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

This trial investigates the effects of FE 200440 compared to placebo on implantation rate in women undergoing IVF/ICSI treatment

Timeline

Start
2012-11
Primary completion
2014-10
Completion
2015-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Barusiban Unknown Subcutaneous

Indications